Market Size of Dengue Testing Industry
![Dengue Testing Market Summary](https://s3.mordorintelligence.com/dengue-testing-market/1645077772801_dengue-testing-market_Market_Summary.webp)
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Market Size (2024) | USD 436.19 Million |
Market Size (2029) | USD 540.20 Million |
CAGR (2024 - 2029) | 4.37 % |
Fastest Growing Market | Asia Pacific |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Dengue Testing Market Analysis
The Dengue Testing Market size is estimated at USD 436.19 million in 2024, and is expected to reach USD 540.20 million by 2029, growing at a CAGR of 4.37% during the forecast period (2024-2029).
The COVID-19 pandemic substantially impacted the dengue testing market. Dengue viruses and SARS-CoV-2 cause similar symptoms in the early stages of infection. Thus, as a result, a significant proportion of the population underwent dengue testing, boosting the market's growth. For instance, as per an article published in IDR in June of the base year, it was observed that the clinical and biochemical characteristics of dengue infection and COVID-19 were identical in two infected patients in Singapore. The two individuals were diagnosed with dengue fever through a positive dengue serological test and were treated for it. However, their symptoms worsened, and a subsequent test revealed that they were COVID-19 positive.
Furthermore, several regions worldwide reported growing dengue cases amid the COVID-19 pandemic. For instance, an article published in July of the base year stated that dengue showed an increasing trend in the number of cases in the country, requiring urgent public policies to curb it. This resulted in an increased demand for testing procedures. Hence, COVID-19 significantly impacted the market's growth during the pandemic.
Certain factors contributing to the market's growth are the increasing incidences of dengue cases and the growth in the number of awareness campaigns to educate about the ills of dengue.
The overall incidence of dengue and the explosive outbreaks of the disease increased dramatically over the last several years. For instance, according to the statistics published by the European CDC, 1,371,248 dengue cases and 849 deaths were reported this year worldwide. In addition, as per the same source, the majority of cases were reported by Brazil (1,114,758), followed by Peru (45,816), Vietnam (25,694), Indonesia (22,331), and Colombia (21,576). Additionally, as per the data published by the WHO and PAHO, as of 1st June this year, there were 1,238,528 dengue cases reported in America, with 544,125 confirmed cases and 426 deaths. Thus, the rising burden of dengue cases across countries is expected to increase the demand for dengue testing, which is anticipated to propel the market's growth over the forecast period.
Similarly, government and healthcare professionals' initiatives to limit dengue spread are expected to boost the market's growth over the forecast period. For instance, in May this year, DoH-CHD ramped up its dengue fever campaign in Soccsksargen after the Regional Epidemiology and Surveillance Unit (RESU) recorded 854 dengue cases in the Philippines from January 1 to April 30 this year.
Moreover, the rising focus of companies on adopting various business strategies, such as acquisition, partnerships, and product launches for dengue testing, is expected to fuel the market's growth. For instance, in September of the base year, the Central Drugs Standard Control Organization (CDSCO) approved Cosara Diagnostics to manufacture and distribute SARAGENE Dengue Test Kit. The test kit is a real-time polymerase chain reaction technology-based in vitro diagnostic test that uses Co-Diagnostics' patented CoPrimers technology. In March of the base year, Roche and GenMark diagnostics entered a definitive merger agreement for Roche to fully acquire GenMark for USD 24.05 per share in an all-cash transaction.
However, the unavailability of effective diagnostic tools and the high price of existing test kits will likely restrain the market's growth over the forecast period.
Dengue Testing Industry Segmentation
As per the scope of the report, dengue is the most rapidly spreading mosquito-borne viral disease in the world. Blood testing detects viruses or antibodies produced in response to dengue infection. Therefore to control the spread of dengue fever, there are various diagnostic tests to reduce the number of deaths and focus on prevention and cure. The dengue testing market is segmented by product type (ELISA-based tests, RT-PCR-based tests, dengue IgG/IgM rapid tests, and other tests), by end-user (hospitals, diagnostic centers, and other end-users), and by geography (Asia-Pacific and Americas). The report offers the value (USD million) for the above segments.
Product Type | |
ELISA-based Tests | |
RT-PCR based Tests | |
Dengue IgG/IgM Rapid Test | |
Other Tests |
End User | |
Hospitals | |
Diagnostic Centers | |
Other End Users |
Geography | ||||||||||
| ||||||||||
|
Dengue Testing Market Size Summary
The dengue testing market is poised for growth, driven by an increasing incidence of dengue cases and heightened awareness campaigns. The COVID-19 pandemic significantly influenced the market, as the overlap in symptoms between dengue and COVID-19 led to a surge in testing. This demand was further fueled by rising dengue cases globally, necessitating urgent public health responses. The market is characterized by the adoption of advanced diagnostic methods, with enzyme-linked immunosorbent assay (ELISA) tests gaining prominence due to their ability to detect dengue virus serotypes and NS1 antigens. Technological advancements in ELISA platforms and the introduction of new diagnostic kits by major players are expected to bolster market expansion.
The Asia-Pacific region is anticipated to be the fastest-growing market, driven by a high prevalence of dengue infections and supportive government initiatives. The region's growth is further supported by the development of innovative diagnostic test kits and strategic partnerships among key industry players. Despite challenges such as the high cost of diagnostic tools, the market is expected to thrive due to the increasing demand for effective testing solutions. The market's consolidation, with significant contributions from companies like Abbott Laboratories and Thermo Fisher Scientific, underscores the competitive landscape and the ongoing efforts to enhance dengue testing capabilities.
Dengue Testing Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increase Incidences of Dengue Cases
-
1.2.2 Increasing Awareness Campaigns to Educate About the Ills of Dengue
-
-
1.3 Market Restraints
-
1.3.1 Unavailability of Effective Diagnostic Tools
-
1.3.2 High Price of Existing Test Kits
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 Product Type
-
2.1.1 ELISA-based Tests
-
2.1.2 RT-PCR based Tests
-
2.1.3 Dengue IgG/IgM Rapid Test
-
2.1.4 Other Tests
-
-
2.2 End User
-
2.2.1 Hospitals
-
2.2.2 Diagnostic Centers
-
2.2.3 Other End Users
-
-
2.3 Geography
-
2.3.1 Asia-Pacific
-
2.3.1.1 India
-
2.3.1.2 Philippines
-
2.3.1.3 Indonesia
-
2.3.1.4 Malaysia
-
2.3.1.5 Vietnam
-
2.3.1.6 Thailand
-
2.3.1.7 Sri Lanka
-
2.3.1.8 Rest of Asia-Pacific
-
-
2.3.2 Americas
-
2.3.2.1 Brazil
-
2.3.2.2 Mexico
-
2.3.2.3 Nicaragua
-
2.3.2.4 Colombia
-
2.3.2.5 Honduras
-
2.3.2.6 Rest of Americas
-
-
-
Dengue Testing Market Size FAQs
How big is the Dengue Testing Market?
The Dengue Testing Market size is expected to reach USD 436.19 million in 2024 and grow at a CAGR of 4.37% to reach USD 540.20 million by 2029.
What is the current Dengue Testing Market size?
In 2024, the Dengue Testing Market size is expected to reach USD 436.19 million.